Lantheus Holdings, Inc.

Good morning. Welcome to the Lantheus fourth quarter and full year 2024 conference call. This is your operator for today's call. Please note that all lines have been placed on mute to limit background noise. This call is being recorded. A replay will be available in the investor section of the company's website approximately two hours after the completion of the call and will be archived for at least 30 days. I'll now turn the call over to your host for today. Mark Conarney, Vice President of Investor Relations. Mark?

Thank you. Good morning and welcome to today's call. With me today are Brian Markeson, our CEO, Paul Blanchfield, our President, Bob Marshall, our CFO, Jeff Humphrey, our Chief Medical Officer, and Amanda Morgan, our Chief Commercial Officer. We will begin the call with prepared remarks and then open the call for Q&A. This morning we issued a press release which was furnished to the SEC under Form 8-K, reporting our second quarter 2024 results. The release and today's slide presentation are in the investor section of our website. Any comments made during our call could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties which are detailed in our SEC filings. Discussions during this call will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the investor section of our website. I will now turn the call over to our CEO, Brian.

Thank you, Mark, and good morning, everyone. At Lantheus, we are the leading radiopharmaceutical-focused company with a clear purpose to find, fight, and follow disease to deliver better patient outcomes. Last quarter, we outlined our strategy to enhance our leadership by maximizing the value of our existing portfolio and expanding our innovative pipeline of radiopharmaceuticals through focused business development and M&A, all while sustaining a strengthening and attractive financial profile. Our continued operational performance, financial discipline, and growing pipeline will enable us to create long-term, sustainable value. We delivered another strong quarter, led by our commercial products, Clarify, DFINITY, and Technolite. I am particularly proud to share that since the beginning of 2024, our products have positively impacted the lives of more than 3.4 million patients and their families. You will hear more about the quarter from Paul and Bob in just a few moments. Beyond our commercial portfolio, we progressed our pipeline and utilized the strength of our balance sheet to execute three strategic transactions. We are expanding our pipeline with a mix of late and early stage assets that have the potential to address high unmet medical needs.